UNLEASHING THE PROMISE OF T-CELL THERAPIES.
Cutting-edge science. A fresh approach.
Off-the-shelf approach
Allogeneic T-cell therapies can be readily available for rapid delivery within days.
Scalable manufacturing
Efficient, robust process with the ability to produce over a thousand doses from one healthy donor.
Highly versatile platform
Potential application for a wide range of disease-causing viral and non-viral targets.
We’re developing a pipeline of firsts.
Our investigational T-cell therapies target difficult-to-treat Epstein-Barr virus (EBV)-driven conditions, including certain cancers and multiple sclerosis, as well as a wide range of non-EBV-associated diseases. We’re the first company ever to receive an approval for an allogeneic T-cell immunotherapy.
Latest news
-
February 08, 2023
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress READ MORE -
December 20, 2022
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty READ MORE -
December 19, 2022
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD READ MORE
Dig deeper.
Explore patient stories, our clinical studies, or visit our investor hub for more information.